caa a22 4500 606157123 CHVBK 20210128100612.0 cr unu---uuuuu 210128e20150401xx s 000 0 eng 10.1007/s10096-014-2297-2 doi (NATIONALLICENCE)springer-10.1007/s10096-014-2297-2 Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012 [Elektronische Daten] [M. van Gent, C. Heuvelman, H. van der Heide, H. Hallander, A. Advani, N. Guiso, C. Wirsing von Kőnig, D. Vestrheim, T. Dalby, N. Fry, D. Pierard, L. Detemmerman, J. Zavadilova, K. Fabianova, C. Logan, A. Habington, M. Byrne, A. Lutyńska, E. Mosiej, C. Pelaz, K. Gröndahl-Yli-Hannuksela, A. Barkoff, J. Mertsola, A. Economopoulou, Q. He, F. Mooi] Despite more than 50years of vaccination, pertussis is still an endemic disease, with regular epidemic outbreaks. With the exception of Poland, European countries have replaced whole-cell vaccines (WCVs) by acellular vaccines (ACVs) in the 1990s. Worldwide, antigenic divergence in vaccine antigens has been found between vaccine strains and circulating strains. In this work, 466 Bordetella pertussis isolates collected in the period 1998-2012 from 13 European countries were characterised by multi-locus antigen sequence typing (MAST) of the pertussis toxin promoter (ptxP) and of the genes coding for proteins used in the ACVs: pertussis toxin (Ptx), pertactin (Prn), type 2 fimbriae (Fim2) and type 3 fimbriae (Fim3). Isolates were further characterised by fimbrial serotyping, multi-locus variable-number tandem repeat analysis (MLVA) and pulsed-field gel electrophoresis (PFGE). The results showed a very similar B. pertussis population for 12 countries using ACVs, while Poland, which uses a WCV, was quite distinct, suggesting that ACVs and WCVs select for different B. pertussis populations. This study forms a baseline for future studies on the effect of vaccination programmes on B. pertussis populations. The Author(s), 2014 van Gent M. Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA, Bilthoven, The Netherlands aut Heuvelman C. Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA, Bilthoven, The Netherlands aut van der Heide H. Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA, Bilthoven, The Netherlands aut Hallander H. The Swedish National Institute of Public Health, Solna, Sweden aut Advani A. The Swedish National Institute of Public Health, Solna, Sweden aut Guiso N. Molecular Prevention and Therapy of Human Diseases, Institut Pasteur, Paris, France aut Wirsing von Kőnig C. Labor: Medizin Krefeld MVZ, Helios Klinikum, Krefeld, Germany aut Vestrheim D. Department of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, Norway aut Dalby T. Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark aut Fry N. Respiratory and Vaccine Preventable Bacteria Reference Unit, Public Health England—Microbiology References Services, Colindale, United Kingdom aut Pierard D. National Reference Center for Pertussis, Department of Microbiology and Infection Control, Universitair Ziekenhuis Brussel, Brussels, Belgium aut Detemmerman L. National Reference Center for Pertussis, Department of Microbiology and Infection Control, Universitair Ziekenhuis Brussel, Brussels, Belgium aut Zavadilova J. National Reference Laboratory for Pertussis and Diphtheria, National Institute of Public Health, Prague, Czech Republic aut Fabianova K. Department of Infectious Diseases Epidemiology, National Institute of Public Health, Prague, Czech Republic aut Logan C. Microbiology Department, Our Lady's Children's Hospital, Dublin, Ireland aut Habington A. Microbiology Department, Our Lady's Children's Hospital, Dublin, Ireland aut Byrne M. Microbiology Department, Our Lady's Children's Hospital, Dublin, Ireland aut Lutyńska A. Department of Sera and Vaccines Evaluation, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland aut Mosiej E. Department of Sera and Vaccines Evaluation, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland aut Pelaz C. Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain aut Gröndahl-Yli-Hannuksela K. Department of Infectious Disease Surveillance and Control, National Institute for Health and Welfare, Turku, Finland aut Barkoff A. Department of Infectious Disease Surveillance and Control, National Institute for Health and Welfare, Turku, Finland aut Mertsola J. Department of Pediatrics, Turku University Hospital, Turku, Finland aut Economopoulou A. European Centre for Disease Control and Prevention (ECDC), Stockholm, Sweden aut He Q. Department of Infectious Disease Surveillance and Control, National Institute for Health and Welfare, Turku, Finland aut Mooi F. Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA, Bilthoven, The Netherlands aut European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/4(2015-04-01), 821-830 0934-9723 34:4<821 2015 34 10096 https://doi.org/10.1007/s10096-014-2297-2 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10096-014-2297-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- van Gent M. Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA, Bilthoven, The Netherlands aut NATIONALLICENCE 700 1- Heuvelman C. Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA, Bilthoven, The Netherlands aut NATIONALLICENCE 700 1- van der Heide H. Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA, Bilthoven, The Netherlands aut NATIONALLICENCE 700 1- Hallander H. The Swedish National Institute of Public Health, Solna, Sweden aut NATIONALLICENCE 700 1- Advani A. The Swedish National Institute of Public Health, Solna, Sweden aut NATIONALLICENCE 700 1- Guiso N. Molecular Prevention and Therapy of Human Diseases, Institut Pasteur, Paris, France aut NATIONALLICENCE 700 1- Wirsing von Kőnig C. Labor: Medizin Krefeld MVZ, Helios Klinikum, Krefeld, Germany aut NATIONALLICENCE 700 1- Vestrheim D. Department of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, Norway aut NATIONALLICENCE 700 1- Dalby T. Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark aut NATIONALLICENCE 700 1- Fry N. Respiratory and Vaccine Preventable Bacteria Reference Unit, Public Health England—Microbiology References Services, Colindale, United Kingdom aut NATIONALLICENCE 700 1- Pierard D. National Reference Center for Pertussis, Department of Microbiology and Infection Control, Universitair Ziekenhuis Brussel, Brussels, Belgium aut NATIONALLICENCE 700 1- Detemmerman L. National Reference Center for Pertussis, Department of Microbiology and Infection Control, Universitair Ziekenhuis Brussel, Brussels, Belgium aut NATIONALLICENCE 700 1- Zavadilova J. National Reference Laboratory for Pertussis and Diphtheria, National Institute of Public Health, Prague, Czech Republic aut NATIONALLICENCE 700 1- Fabianova K. Department of Infectious Diseases Epidemiology, National Institute of Public Health, Prague, Czech Republic aut NATIONALLICENCE 700 1- Logan C. Microbiology Department, Our Lady's Children's Hospital, Dublin, Ireland aut NATIONALLICENCE 700 1- Habington A. Microbiology Department, Our Lady's Children's Hospital, Dublin, Ireland aut NATIONALLICENCE 700 1- Byrne M. Microbiology Department, Our Lady's Children's Hospital, Dublin, Ireland aut NATIONALLICENCE 700 1- Lutyńska A. Department of Sera and Vaccines Evaluation, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland aut NATIONALLICENCE 700 1- Mosiej E. Department of Sera and Vaccines Evaluation, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland aut NATIONALLICENCE 700 1- Pelaz C. Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain aut NATIONALLICENCE 700 1- Gröndahl-Yli-Hannuksela K. Department of Infectious Disease Surveillance and Control, National Institute for Health and Welfare, Turku, Finland aut NATIONALLICENCE 700 1- Barkoff A. Department of Infectious Disease Surveillance and Control, National Institute for Health and Welfare, Turku, Finland aut NATIONALLICENCE 700 1- Mertsola J. Department of Pediatrics, Turku University Hospital, Turku, Finland aut NATIONALLICENCE 700 1- Economopoulou A. European Centre for Disease Control and Prevention (ECDC), Stockholm, Sweden aut NATIONALLICENCE 700 1- He Q. Department of Infectious Disease Surveillance and Control, National Institute for Health and Welfare, Turku, Finland aut NATIONALLICENCE 700 1- Mooi F. Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA, Bilthoven, The Netherlands aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/4(2015-04-01), 821-830 0934-9723 34:4<821 2015 34 10096